We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Cloud Computing Platform Helps Researchers Study Large Quantities of DNA Sequence Data

By LabMedica International staff writers
Posted on 01 Dec 2011
An open-source, web-based platform for data-intensive biomedical and genetic research, is now available as a “cloud computing” resource. More...


A team of researchers including Dr. Anton Nekrutenko, an associate professor of biochemistry and molecular biology at Pennsylvania State University (Penn State; University Park, USA); Dr. Kateryna Makova, an associate professor of biology at Penn State; and James Taylor from Emory University (Atlanta, GA, USA), devised the new technology, which will help scientists and biomedical researchers to exploit such tools as DNA-sequencing and analysis software, as well as storage capacity for large quantities of scientific data. Details of the development are to be published as a letter in the journal Nature Biotechnology.

Dr. Nekrutenko reported that he and his team first developed the Galaxy computing system in 2005 because “biology is in a state of shock. Biochemistry and biology labs generate mountains of data, and then scientists wonder, ‘What do we do now? How do we analyze all these data?’” Galaxy, which was developed at Penn State and continues to use the University's servers for its computing power, solves many of the problems that researchers encounter by pulling together a variety of tools that allow for easy retrieval and analysis of large amounts of data, simplifying the process of genomic analysis.

As described in one of the scientists’ early articles in the journal Genome Research, Galaxy, “combines the power of existing genome-annotation databases with a simple Web portal to enable users to search remote resources, combine data from independent queries, and visualize the results.” Galaxy also allows other researchers to be able to review the steps that have been taken, for example, in the analysis of a string of genetic code. “Galaxy offers scientific transparency--the option of creating a public report of analyses. So, after a paper has been published, scientists in other labs can do studies in order to reproduce the results described,” Dr. Nekrutenko said.

Now, the scientists have taken Galaxy to the next phase by developing an “in-the-cloud” option using, for example, the popular Amazon Web Services cloud. “A cloud is basically a network of powerful computers that can be accessed remotely without the need to worry about heating, cooling, and system administration. Such a system allows users, no matter where they are in the world, to shift the workload of software storage, data storage, and hardware infrastructure to this remote location of networked computers,” Dr. Nekrutenko explained. “Rather than run Galaxy on one’s own computer or use Penn State’s servers to access Galaxy, now a researcher can harness the power of the cloud, which allows almost unlimited computing power.”

As a case study, the scientists report on recent research published in Genome Biology in which scientists, with the help of Ian Paul, a professor of pediatrics at Penn State’s Hershey Medical Center, analyzed DNA from nine individuals across three families using Galaxy Cloud. Due to the enormous computing power of the platform, the researchers were able to identify four heteroplasmic sites--variations in mitochondria, the part of the genome passed only from mother to child.

“Galaxy Cloud offers many advantages other than the obvious ones, such as computing power for large amounts of data and the ability for a scientist without much computer training to use DNA-analysis tools that might not otherwise be accessible,” Dr. Nekrutenko concluded. “For example, researchers need not invest in expensive computer infrastructure to be able to perform data-intensive, sophisticated scientific analyses.”

Moreover, another benefit of Galaxy Cloud is its data-storage capacity. Using the Amazon Web Services cloud, researchers have the option of storing vast amounts of data in a secure location. “There are emerging technologies that will produce 100 times more data than existing next-generation DNA sequencing, which already has reached the point where even more storage becomes an issue, not to mention analysis,” Dr. Nekrutenko said.

Related Links:
Pennsylvania State University
Emory University


Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Automatic Western Blot Analyzer
Tenfly Phoenix Blot Analyzer
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.